Mumbai, June 21, 2017: Pharma Major,Cadila Healthcare Ltd (Zydus Cadila) today said it has received final approval from the USFDA to market Diflunisal tablets in the strength of 500 mg.
It is a non-steroidal anti-inflammatory drug (NSAID) and will be produced at the group’s formulations manufacturing facility at Baddi, Himachal Pradesh, company said in a filing with BSE.
United News of India
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…